Vaxcyte Inc is primarily active in the healthcare sector.

The main competitors of Vaxcyte Inc in the market include companies such as Pfizer, Moderna, Novavax, and AstraZeneca.

Vaxcyte Inc is a leading biotechnology company specializing in the development of novel vaccines to combat infectious diseases. Established in [year], Vaxcyte has a rich history of pioneering research and collaboration with renowned institutions. With a mission to enhance global health through innovative vaccine solutions, the company has made significant strides in targeting various pathogens. Headquartered in [location], Vaxcyte has amassed a team of talented scientists and industry experts dedicated to improving public health worldwide. Leveraging cutting-edge technologies and a robust pipeline, Vaxcyte Inc continues to make remarkable advancements in the field of vaccine development.

Vaxcyte Inc, a leading biotechnology company, has achieved numerous significant milestones. Notably, the company successfully completed its initial public offering (IPO) in June 2020, raising substantial funds to drive its innovative research and development efforts. Vaxcyte has also made remarkable progress in the development of its investigational pneumococcal conjugate vaccine, VAX-24. This vaccine candidate has shown promising results in clinical trials, demonstrating its potential to prevent pneumococcal diseases in both pediatric and adult populations. Furthermore, Vaxcyte has established strategic partnerships and collaborations with renowned organizations and experts in the field, further fueling its growth and market presence. Overall, Vaxcyte Inc has achieved significant milestones in its pursuit of improving global public health through innovative vaccine solutions.

Vaxcyte Inc is primarily present in the United States.

Vaxcyte Inc embodies a strong commitment to advancing global health through innovative vaccine solutions and effective disease prevention. With a core philosophy rooted in scientific excellence, Vaxcyte strives to develop and deliver transformative immunizations to protect vulnerable populations. The company's values revolve around integrity, collaboration, and persistence in the pursuit of groundbreaking vaccine research and development. Vaxcyte's dedicated team of experts works tirelessly to address unmet medical needs, focusing on infectious diseases and finding efficient ways to enhance public health. Through its unwavering dedication and pioneering spirit, Vaxcyte Inc aims to make a lasting impact in the field of immunization.

Analysts currently set an average price target of 102.23 USD for the Vaxcyte stock (median: 112.20 USD), implying +89.0 % versus the latest price. The consensus is based on 17 analyst ratings.

Vaxcyte Analyst Price Targets 2026

17 analysts currently rate the Vaxcyte stock: 15 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Vaxcyte to generate revenue of 25.00 M USD and earnings per share of -8.38 USD.

Vaxcyte Analyst Price Targets 2026

Converted at the current exchange rate, the Vaxcyte share trades at 46.98 EUR (54.08 USD).

The Vaxcyte share (PCVX) is listed on 3 stock exchanges, including: NASDAQ (PCVX), Frankfurt (5VA.F), München (5VA.MU).

Vaxcyte Inc is a biopharmaceutical company specializing in the development and commercialization of vaccines. The company was founded in 2018 in California and has since developed a variety of innovative technologies and platforms to combat a wide range of infectious diseases. Vaxcyte's business model is based on the development and commercialization of vaccines for diseases that currently have a high medical need. The company uses a recognized technology platform to identify potential vaccine candidates and conducts comprehensive clinical trials to ensure the effectiveness and safety of vaccines. Vaxcyte has particularly specialized in vaccines against pneumococcal infections, which can lead to serious illnesses such as pneumonia, meningitis, and sepsis. The company also has a wide range of vaccines in the pipeline targeting other severe infectious diseases, including chlamydia, gonorrhea, and RSV (respiratory syncytial virus). Vaxcyte has also developed a specialized technology platform to expand the potential of therapies aiming to remove antibiotics from the vaccine manufacturing process. Vaxcyte also maintains relationships with partners and investors who support its funding and business development. The company also receives external support as it has strong connections to academic institutions and national and international regulatory authorities such as the FDA and EMA, which grant important approvals for clinical trials and marketing authorizations. Vaxcyte aims to ensure successful development and commercialization of vaccines that are effective and safe through adequate regulation and industry knowledge. The company strives to optimize the end-to-end development of vaccines by using its technology to identify vaccine candidates with high potential for success in combating serious infectious diseases. In addition to the above-mentioned business areas, Vaxcyte also offers product services, particularly in collaboration with other companies looking to introduce products or technologies to the marketplace. By providing expertise in pharmacology, development, and procedural processes, Vaxcyte can help companies turn their innovative ideas into functional products. Overall, Vaxcyte's business model aims to develop innovative and effective vaccine solutions for a variety of serious infectious diseases to address global health needs. The use of cutting-edge technology and collaboration with other companies forms the foundation for the company's success.

The expected revenue of Vaxcyte is 25.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Vaxcyte is -1.14 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Vaxcyte is currently -6.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Vaxcyte stock.

The price-to-sales ratio (P/S) of Vaxcyte is currently 294.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Vaxcyte stock.

The Eulerpool Quality Score for Vaxcyte is 2/10.

The ISIN of Vaxcyte is US92243G1085. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Vaxcyte is A2P6R6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Vaxcyte is PCVX. The ticker symbol is used to trade Vaxcyte shares on the stock exchange.

Vaxcyte paid dividends every year for the past 0 years.

Vaxcyte is assigned to the 'Health' sector.

The dividends of Vaxcyte are distributed in USD.